ReviewTherapeutic advances in musculoskeletal disease2026
MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions.
Review in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Multiple chronic conditions (MCCs), also known as multimorbidity, are highly prevalent in adults with autoimmune and inflammatory rheumatic diseases (AIIRDs) and significantly complicate their management. This narrative review summarizes current literature on the epidemiology of MCCs in various AIIRDs, highlighting their association with adverse health outcomes and proposing future directions for care. MCCs are ubiquitous across AIIRDs, often exceeding rates seen in age-matched general populations, with prevalence as high as 86% in rheumatoid arthritis and 81.5% in systemic lupus erythematosus cohorts and notable patterns including cardiopulmonary and mental health disorders frequently observed. This substantial MCC burden is consistently linked to adverse outcomes, including increased all-cause mortality, reduced functional status, diminished health-related quality of life, accelerated disability, higher healthcare utilization, and increased costs, driven by chronic inflammation, lifestyle, and treatment effects. Therefore, rheumatology care must adopt a holistic, person-centered framework that actively recognizes and manages MCCs, leveraging multidisciplinary teams and integrating evidence-based interventions guided by frameworks such as the geriatric 5Ms and 5Ts to advance the science of MCCs in adults with AIIRDs and improve outcomes and optimize health-related quality of life in this complex patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.